



55,000.00

1		31,301.88	26,500.00
2		15,000.00	12,500.00
3		16,000.00	16,000.00
		<b>62,301.88</b>	<b>55,000.00</b>

1

2

3.22

/ 21.45 /

2

3.13

	1	2	3	4	1	2	3	4
GMP								

1	30,101.88	26,500.00	96.17%
1.1	27,855.35	26,500.00	88.99%
1.1.1	15,266.42	14,500.00	48.77%
1.1.2	12,588.93	12,000.00	40.22%
1.2	1,446.52	-	4.62%
1.3	800.00	-	2.56%
2	1,200.00	-	3.83%
<b>3</b>	<b>31,301.88</b>	<b>26,500.00</b>	<b>100%</b>
	31,301.88	26,500.00	

2

1

2018

2

			HBV	7,000	
CHB	2,000	3,000	HCV		1,000

90%

3

**4**

2017 146

**3**

**1**

1		
2		
3		

WHO 2015

2.57

68%

88.7

HBsAg

5% 6%

7,000

2,000

3,000

2011

68.81

2015

162.76

22.4%

GlobalData

2020

200

80%

TAF

TAF

2016

11

FDA

2018

11

2019

TAF

TAF

TAF

2019 11 4

2021

HCV

HCV

DAA's

2014

2017-2020

2020

HCV

100%

-HCV

2018 ED  
28.5  
60% ED 50  
ED ED

2019 7 30  
2020 12 31

2

3

7,533.25

11,396.54

7,004.78

80

4

3.13

2

37,441.02

5,462.80

5

1

2

		2019 J070028
		2020 1
		2020 H020004
		2020 34

1

2.5

10 /

1 /

2.5

1.50

	2.5				1.50					
	1	2	3	4	1	2	3	4	1	2
GMP										

1		14,427.03	12,500.00
1.1		13,273.22	12,500.00
1.1.1		7,344.09	7,000.00
1.1.2		5,929.13	5,500.00
1.2		825.99	-
1.3		327.82	-
2		572.97	-
<b>3</b>		<b>15,000.00</b>	<b>12,500.00</b>

15,000.00

12,500.00

2

1

2030

2020

15,823

15%

29.26%

33.26%

2

3

15-64  
2030 60 30%

**3**

**1**

1		
2		

2019

8% 30%

10,000

2020 1 1-20  
43

Lancet  
99  
1

2018

1.2

2018

330

2



42,345.38

3,370.07

5

1

2

	2019 260
	2019 72

1

16,000

29.09%

30%

2

1

2019

7,533.25	11,396.54	7,004.78
25.44%	28.32%	16.88%

GST-HG161	2019	7	9	c-MET
I				
FACO				CSCO
				I
GST-HG151				GST-HG141
2019	11	2020	3	GST-HG131
				2019
				4
				GST-HG141
				2020
				5
				28
				GST-HG141
				2020
				6
				16

2

25.04%	34.21%	35.74%
--------	--------	--------

2020 6 19